Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), will present four abstracts at the virtual American Society for Dermatologic Surgery (ASDS) meeting from October 9-11, 2020. Key presentations include:
- Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers, presented by Joely Kaufman on October 10 at 11:27 a.m..
- Treatment of Upper Facial Lines With OnabotulinumtoxinA, presented by Joel L. Cohen on October 11 at 10:27 a.m..
The abstracts will focus on safety, efficacy, and patient satisfaction related to aesthetic treatments.
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced its agreement to acquire Luminera, an Israel-based aesthetics company specializing in dermal fillers. This acquisition will enhance Allergan's existing JUV DERM® filler portfolio with Luminera's innovative products, including the differentiated HArmonyCa filler. The deal aims to strengthen Allergan Aesthetics' position in the global aesthetics market, providing new offerings for healthcare professionals and patients. The full dermal filler portfolio will also support international development opportunities.
AbbVie will announce its third-quarter 2020 financial results on October 30, 2020, before market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. Central time. The event can be accessed through AbbVie's Investor Relations website, with an archived version available later that day. AbbVie is dedicated to developing innovative medicines for serious health issues in various therapeutic areas.
AbbVie (NYSE: ABBV) announced its participation at the 2020 Virtual Migraine Trust International Symposium from October 3-9, showcasing findings from 15 clinical trials. Key highlights include new data from the Phase 3 ADVANCE trial for atogepant, a CGRP receptor antagonist aimed at migraine prevention. The symposium will feature oral presentations on October 7, outlining atogepant’s efficacy and safety, as well as research on BOTOX® and UBRELVY®. The ongoing efforts reflect AbbVie's commitment to advancing migraine treatment amid a significant global health burden affecting over 1 billion individuals.
AbbVie announced that the FDA has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational monoclonal antibody targeting spinal cord injury. Elezanumab aims to promote neuronal regeneration by inhibiting repulsive guidance molecule A (RGMa) and is currently in a phase 2 study. The company is partnering with Shirley Ryan AbilityLab and MC10 for a pilot study to optimize treatment approaches. These designations highlight AbbVie's commitment to addressing serious medical conditions and potentially expediting the development of new therapies for patients.
Allergan Aesthetics, part of AbbVie, has announced actress Malin Akerman as the first U.S. ambassador for its body contouring portfolio, which includes CoolSculpting® and CoolTone™. Both treatments cater to non-surgical fat reduction and muscle toning. Akerman has personally benefited from these procedures, targeting stubborn fat and enhancing muscle strength. With over 4 million people considering non-invasive body contouring, the partnership aims to educate consumers on these options. Special promotional gift cards are available for CoolSculpting and CoolTone treatments until the end of 2020.
AbbVie (NYSE: ABBV) will present findings from numerous studies, including the DYSCOVER study on DUODOPA® and advanced Parkinson's disease, during the 2020 International Congress of Parkinson's Disease and Movement Disorders, from September 12-16. The 12-week DYSCOVER study is the first to compare DUODOPA's efficacy against optimized medical treatment on dyskinesia, an involuntary movement symptom. Additionally, data on ABBV-951, a new treatment for advanced PD, will also be showcased. Overall, 18 abstracts will be presented, highlighting AbbVie's commitment to addressing Parkinson's disease challenges.
AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.18 per share, payable on November 16, 2020, to stockholders of record as of October 15, 2020.
Since its inception, AbbVie has increased its dividend by 195% and is part of the S&P Dividend Aristocrats Index, recognizing companies with a history of annual dividend increases over 25 years.
AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 10 a.m. Central time. CEO Richard A. Gonzalez will present, and the session will be available via a live audio webcast on AbbVie's Investor Relations website, with an archived edition accessible later that day.
AbbVie aims to deliver innovative medicines across key therapeutic areas, including immunology, oncology, and neuroscience, and has a commitment to address serious health challenges.
AbbVie has submitted applications to the FDA and EMA for RINVOQ (upadacitinib) to treat active ankylosing spondylitis. This selective JAK inhibitor aims to address significant treatment gaps for patients suffering from this debilitating condition. The FDA application is backed by the SELECT-AXIS 1 Phase 2/3 trial, which showed that 52% of patients on RINVOQ met the treatment endpoint compared to 26% on placebo (p0.001). RINVOQ previously gained approval for rheumatoid arthritis, but its safety and efficacy for ankylosing spondylitis remain unestablished. Innovation in this area is crucial given the limited options available.